COPENHAGEN, Denmark, March 11, 2026 (GLOBE NEWSWIRE)-- Commit Biologics (“Commit”), a biotechnology company pioneering complement system activation and backed by €21.5 million in seed financing from ...
Follow-up on phase 1 study of AT101, a novel anti-CD19 chimeric antigen receptor cell therapy (CAR-T) in patients with relapsed or refractory (r/r) b-cell non-Hodgkin lymphoma. This is an ASCO Meeting ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results